The 25.11 Data Release includes updates to human studies including longitudinal metabolomic data from ADNI Cohorts, RNA-seq data from Mayo Clinic studies, and a proteoform discovery dataset from the ROSMAP study.

Proper acknowledgment of data sources is not only mandatory for users of the AD Knowledge Portal, it also enhances the visibility of your work and elevates recognition of datasets used. All data use must be acknowledged with the following: the AD Knowledge Portal Acknowledgement Statement; and an Acknowledgement Statement specific to the study/dataset used, from the relevant Study page; and a Data Availability statement that includes a direct link to access relevant resources, known as a dataset DOI. For more information and pre-written acknowledgement statements, see Data Use & Acknowledgement.

Human

  • The VirusResilience_Organoids Study

    The VirusResilience_Organoids study provides an analysis of cerebral organoids obtained from a Personal Genome Project (PGP) donor.

    • This release provides RNA sequencing and flow cytometry files generated using human primary skin fibroblasts. It also provides clinical metadata for a single individual.

  • The ADMCLongitudinalADNIMetabolon Study

    The ADMCLongitudinalADNIMetabolon study seeks to understand the metabolomics of cognitive decline in the ADNI 1 and ADNI GO/2 Cohorts.

    • This release provides clinical and assay metadata files for this study. Detailed clinical and demographic information on individuals in these studies can be found in the UCSF Laboratory of Neuroimaging (LONI) database.

  • The MC-CAA Study

    This study provides transcriptomic, genotype, and immunoassay data from two related Mayo Clinic studies focused on cerebral amyloid angiopathy (CAA), utilizing post-mortem tissue samples from individuals neuropathologically diagnosed with Alzheimer’s disease. 

    • This release adds raw bisulfite sequencing and RNA sequencing files sourced from temporal cortex and cerebellum samples; it also provides updated clinical and assay metadata.

  • The ADMC_ADNI_Biocrates_MxP_Q500 Study

    This study aims to measure the levels of selected metabolites in 4891 human serum samples from both the ADNI-1 and ADNI-GO/2 phases of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study using the Biocrates MxP® Quant 500 kit. The MxP® Quant 500 assay targets over 600 metabolites from twenty-six compound groups and includes all requisite calibration standards, internal standards, and QC samples. There are five separate mass spectrometric analyses of each sample. 

    • This release updates the URLs for all of the existing LONI files.

  • The ROSMAP_Proteoform Study

    This study provides a proteoform discovery dataset for 103 samples from the ROSMAP study.

    • This release provides cross-tab summaries of the top-down LC-MS/MS proteomics data for 103 ROSMAP samples and corresponding clinical metadata.

  • The Boston University Alzheimer’s Disease Research Center circular RNAs Study

    • The study provides integrative analyses of ADSP genetic data with circRNA and RNA-binding protein networks from human brain tissues to uncover novel functional RNA elements implicated in ADRD. High-throughput functional evaluation of top candidate circRNAs and RBPs in a 3D human organoid model, offers insights into disease mechanisms, biomarkers, and therapeutic targets.
      • This release includes RNA-seq gene expression data investigating how circRNAs and their interacting RNA-binding proteins contribute to Alzheimer’s disease and related dementias. It supports the discovery and characterization of AD-related circRNAs and circRNA–RBP interactions by enabling integrative analyses across brain regions and genomic contexts.